Brokerages Set Telix Pharmaceuticals Limited (NASDAQ:TLX) PT at $21.00

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $21.00.

Several analysts have commented on TLX shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. Finally, Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers lifted its stake in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth approximately $213,000. Blair William & Co. IL bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $217,000. Private Advisor Group LLC boosted its holdings in Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after acquiring an additional 16,945 shares during the period. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals during the 2nd quarter valued at $297,000.

Telix Pharmaceuticals Price Performance

TLX stock opened at $7.61 on Wednesday. The company’s fifty day moving average price is $8.44 and its 200-day moving average price is $10.28. Telix Pharmaceuticals has a one year low of $7.16 and a one year high of $30.36.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.